nmsg

Nerviano Medical Sciences to present a novel orally available selective small molecule Cdc7 inhibitor at the AACR Annual Meeting 2014

Nerviano, Feb 25, 2014. – Nerviano Medical Sciences will disclose data on a novel orally available selective small molecule Cdc7 inhibitor at the AACR Annual Meeting 2014.

NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer. Montagnoli, A et al.

Abstract number: 4539/25. Presentation time: Tue, Apr 08, 1:00 - 5:00 PM

Further details will be disclosed when abstract bodies will be made available on the conference website, at the following link.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.